Table 4 TEAEs in patients with LMD from any solid tumor

All

21 (95.5%)

15 (68.2%)

Blood and lymphatic system disorders

12 (54.6%)

5 (22.7%)

 Anaemia

9 (40.9%)

1 (4.5%)

 Neutropenia

6 (27.3%)

3 (13.6%)

 Thrombocytopenia

5 (22.7%)

1 (4.5%)

 Lymphopenia

3 (13.6%)

1 (4.5%)

 Febrile neutropenia

1 (4.5%)

1 (4.5%)

General disorders and administration site conditions

12 (54.6%)

1 (4.5%)

 Asthenia

6 (27.3%)

0 (0.0%)

 Fatigue

1 (4.5%)

1 (4.5%)

Gastrointestinal disorders

13 (59.14%)

1 (4.5%)

 Nausea

7 (31.8%)

0 (0.0%)

 Diarrhea

6 (27.3%)

1 (4.5%)

 Constipation

3 (13.6%)

0 (0.0%)

 Vomiting

3 (13.6%)

0 (0.0%)

 Ascites

1 (4.5%)

1 (4.5%)

Nervous system disorders

10 (45.5%)

3 (13.6%)

 Headache

5 (22.7%)

1 (4.5%)

 Dizziness

3 (13.6%)

0 (0.0%)

 Disturbance in attention

2 (9.1%)

1 (4.5%)

 Seizure

2 (9.1%)

1 (4.5%)

Investigations

7 (31.8%)

1 (4.5%)

 Alanine aminotransferase increased

5 (22.7%)

0 (0.0%)

 Aspartate aminotransferase increased

4 (18.2%)

0 (0.0%)

 Transaminases increased

1 (4.5%)

1 (4.5%)

Metabolism and nutrition disorders

7 (31.8%)

1 (4.5%)

 Hypocalcaemia

1 (4.5%)

1 (4.5%)

Skin and subcutaneous tissue disorders

7 (31.8%)

0 (0.0%)

 Alopecia

3 (13.6%)

0 (0.0%)

Infections and infestations

7 (31.8%)

2 (9.1%)

 Abdominal infection

1 (4.5%)

1 (4.5%)

 Moraxella infection

1 (4.5%)

1 (4.5%)

Respiratory, thoracic and mediastinal disorders

6 (27.3%)

3 (13.6%)

 ILD

2 (9.1%)

1 (4.5%)

 Pulmonary embolism

2 (9.1%)

1 (4.5%)

 Dyspnea

1 (4.5%)

1 (4.5%)

Musculoskeletal and connective tissue disorders

7 (31.8%)

2 (9.1%)

 Muscular weakness

2 (9.1%)

2 (9.1%)

 Fistula

1 (4.5%)

1 (4.5%)

Hepatobiliary disorders

1 (4.5%)

1 (4.5%)

 Jaundice

1 (4.5%)

1 (4.5%)

 Hyperbilirubinemia

1 (4.5%)

1 (4.5%)

Injury, poisoning and procedural complications

1 (4.5%)

1 (4.5%)

 Fall

1 (4.5%)

1 (4.5%)

Neoplasms benign, malignant and unspecified (including cysts and polyps)

1 (4.5%)

1 (4.5%)

 Cancer pain

1 (4.5%)

1 (4.5%)